Catalog No.
Product Name
Application
Product Information
Citations
-
RIPK1 inhibitor
Necrostatin-1 is an ATP-competitive, allosteric inhibitor of receptor-interacting protein kinase 1 (RIPK1) (EC50 = 182 nM).- Cheng Chen, .et al. , Neurochem Res, 2025, Mar 18;50(2):122 PMID: 40100474
- Binjie Yan, .et al. , Cell Death Discov, 2023, 9: 456 PMID: 38097554
-
RIP1 inhibitor
GSK481 is a novel benzoxazepinone (BOAz) series of RIP1 inhibitors. Receptor Interacting Protein Kinase 1 (RIP1) has been implicated as a key contributor to inflammation through the regulation of programmed necrosis. Inhibition of this kinase has been shown to hinder cell necrotic death, thereby establishing RIP1 as a viable target for the potential treatment of multiple inflammatory diseases. -
necroptosis inhibitor
GSK2593074A (GSK??074) is a necroptosis inhibitor with dual targeting ability to both RIP1 and RIP3. -
RIP2 kinase inhibitor
GSK2983559 active metabolite is a receptor interacting protein-2 (RIP2) kinase inhibitor extracted from patent WO/2014043446 A1, compound example 1.
-
RIP2 kinase inhibitor
RIP2 kinase inhibitor 2 is a receptor interacting protein-2 (RIP2) kinase inhibitor extracted from patent WO/2014043437 A1, compound example 9. -
RIPK1 inhibitor
RIPK1-IN-7 is a potent and selective RIPK1 inhibitor with a Kd of 4 nM and an enzymatic IC50 of 11 nM. RIPK1-IN-7 exhibits excellent antimetastasis activity in the experimental B16 melanoma lung metastasis model. -
RIPK1 inhibitor
RIPK1-IN-3 (Example 38), a RIPK1 inhibitor, extracted from patent WO2018148626A1, possesses anti-inflammatory proprieties. -
RIP1 kinase inhibitor
GSK2982772 is a potent, orally active and ATP competitive RIP1 kinase inhibitor with IC50 values of 16 nM and 20 nM for human and monkey RIP1, respectively. -
RIP1 kinase inhibitor
GSK3145095 is a RIP1 kinase inhibitor with an IC50 of 6.3 nM . -
RIP2 inhibitor
RIP2 Kinase Inhibitor 3 is a highly potent and selective inhibitor of receptor interacting protein-2 (RIP2) Kinase with an IC50 of 1 nM . -
RIP1 kinase inhibitor
RIPK1-IN-4 (compound 8) is a potent and selective type II kinase inhibitor of receptor interacting protein 1 (RIP1) kinase and binds to a DLG-out inactive form of RIP1 with an IC50s of 16 nM and 10 nM for RIP1 and ADP-Glo kinase. -
RIP2 kinase inhibitor
GSK2983559 free acid (compound 3) is a potent, specific and oral bioavailable receptor interacting protein 2 (RIP2) kinase inhibitor. -
PROTAC RIPK degrader
PROTAC RIPK Degrader-2 is a non-peptidic, VHL-based PROTAC that selectively targets the serine/threonine kinase RIPK2 for degradation. It promotes cancer cell death and ion channel activation, while also inhibiting key protein interactions involved in disease pathways, including those related to cancer and diabetes. -
PROTAC RIPK degrader
PROTAC RIPK degrader-6 is a Cereblon-based protein-targeting chimeric molecule designed for the degradation of RIP Kinase. This compound employs a RIP2 kinase inhibitor linked through a suitable spacer to a cereblon ligand, facilitating targeted proteolysis of RIPK. Prominent applications include investigations into kinase-related signaling pathways and the development of innovative therapeutic strategies for diseases associated with RIPK dysregulation. -
RIPK3 Inhibitor
GSK-872 hydrochloride is a potent inhibitor of receptor-interacting protein kinase 3 (RIPK3), exhibiting an IC50 of 1.8 nM for binding to the RIP3 kinase domain and an IC50 of 1.3 nM for inhibiting its kinase activity. This compound effectively reduces RIPK3-mediated necroptosis and inhibits the cytoplasmic translocation and expression of HMGB1. Additionally, GSK-872 hydrochloride has been shown to alleviate brain edema and neurological deficits in models of early brain injury, making it a valuable tool for studying necroptosis and related pathophysiological processes. -
RIPK1 Inhibitor
TP-030-1 is a potent inhibitor of receptor-interacting protein kinase 1 (RIPK1). It demonstrates a high affinity for human RIPK1 with a Ki value of 3.9 nM and an IC50 of 4.2 μM for mouse RIPK1. This compound is valuable for investigating the mechanisms underlying inflammatory and neurodegenerative diseases, providing insights into potential therapeutic interventions. -
RIPK2 Inhibitor
CSLP37 is a selective inhibitor of receptor-interacting protein kinase 2 (RIPK2), exhibiting an IC50 of 16.3 nM. This compound effectively suppresses cellular responses mediated by NOD1 and NOD2, while showing no significant inhibitory activity against RIPK1 and RIPK3. CSLP37 is a valuable tool for research into inflammatory signaling pathways and the role of RIPK2 in various diseases. -
RIPK1 Inhibitor
Cl-Necrostatin-1 is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1). It effectively blocks TNF-α-induced necroptosis in Jurkat cells lacking FADD, with an EC50 of 180 nM, thereby preventing caspase activation linked to death-domain receptor signaling. Additionally, Cl-Necrostatin-1 has been shown to decrease infarct size in a mouse model of middle cerebral artery occlusion (MCAO), making it a valuable tool for research in cardiovascular and cerebrovascular pathologies. -
RIPK1 Inhibitor
ZB-R-55 is a potent orally active inhibitor of receptor-interacting protein kinase 1 (RIPK1). This compound exhibits significant potential in modulating cell death pathways and inflammation, making it a valuable tool for researching sepsis and other inflammatory conditions. Its ability to selectively inhibit RIPK1 supports investigations into therapeutic strategies for diseases characterized by dysregulated necroptosis. -
RIPK3 Inhibitor
RIPK3-IN-3 is a selective inhibitor of the receptor-interacting protein kinase 3 (RIPK3), with an IC50 of 10 nM. This compound effectively prevents the phosphorylation of Mixed Lineage Kinase (MLKL), thereby inhibiting oligomerization of p-MLKL and subsequently blocking necroptosis. Additionally, RIPK3-IN-3 has been shown to downregulate CXCL5 secretion and suppress migration and invasion in AsPC-1 cancer cells, making it a valuable tool for studying necroptosis and related pathways in cancer research. -
RIPK1 Inhibitor
TP-030-2 is a potent RIPK1 inhibitor, with a human Ki of 0.43 nM and a mouse IC50 of 100 nM. This compound is designed for research applications targeting necroptosis and inflammatory pathways, making it a valuable tool for investigating cell death mechanisms and disease processes related to RIPK1 signaling. Its high specificity and efficacy support investigations into therapeutic strategies for conditions involving dysregulated cell death. -
RIPK1 Inhibitor
SZM679 is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1) with a Kd value of 8.6 nM, demonstrating high specificity over RIPK3 (>5000 nM). This compound effectively reverses tumor necrosis factor-induced systemic inflammatory responses and reduces Tau hyperphosphorylation and neuroinflammation in the hippocampus and cortex. SZM679 has significant potential for research applications in Alzheimer's disease and other neurodegenerative disorders. -
RIPK1 Inhibitor
Necrostatin-34 is a potent inhibitor of receptor-interacting protein kinase 1 (RIPK1). It stabilizes the inactive conformation of RIPK1 by binding to a specific pocket within the kinase domain, thereby preventing its activation. This compound is primarily utilized in research to explore necroptosis and cell death pathways, making it valuable for studies in inflammation, neurodegeneration, and cancer. -
RIPK1 Inhibitor
RI-962 is a potent and selective inhibitor of receptor-interacting protein kinase 1 (RIPK1), exhibiting an IC50 value of 35.0 nM. This compound is applicable in research focused on neurodegenerative disorders and inflammatory diseases, where modulation of RIPK1 activity can provide insights into disease mechanisms and potential therapeutic strategies. -
RIPK2/ALK2 Inhibitor
OD36 hydrochloride is a potent inhibitor of receptor-interacting protein kinase 2 (RIPK2) and an effective modulator of activin receptor-like kinase 2 (ALK2), exhibiting an IC50 of 5.3 nM against RIPK2. This macrocyclic compound demonstrates strong binding affinity for the ALK2 kinase ATP pocket, with a Kd of 37 nM. OD36 hydrochloride is suitable for research applications focused on signaling pathways involving RIPK2 and ALK2, relevant in studying various diseases, including inflammation and cancer. -
RIPK1 Inhibitor
AV123 is a potent RIPK1 inhibitor with an IC50 of 12.12 µM. This non-cytotoxic compound effectively blocks TNF-α-induced necroptosis, exhibiting an EC50 of 1.7 µM, while leaving apoptotic pathways unaffected. AV123 is valuable for investigating necrotic conditions, including ischemia-reperfusion injuries in the brain, heart, and kidney, as well as in various inflammatory and neurodegenerative diseases. -
RIPK1 Inhibitor
Oditrasertib is a selective reversible inhibitor of receptor-interacting protein kinase 1 (RIPK1), demonstrating oral bioavailability and the ability to penetrate the blood-brain barrier. It is primarily utilized in research related to chronic inflammatory diseases of the central nervous system, including amyotrophic lateral sclerosis and multiple sclerosis. Oditrasertib provides valuable insights into the mechanisms of RIPK1-mediated signaling pathways, aiding in the development of potential therapeutic strategies for these conditions. -
RIPK1 Inhibitor
Eclitasertib is a potent inhibitor of receptor-interacting protein kinase 1 (RIPK1), exhibiting an IC50 of 0.0375 µM. This compound is crucial for studying signaling pathways related to inflammation and cell death, making it valuable for research applications in apoptosis, neurodegeneration, and autoimmune diseases. Eclitasertib provides an effective tool for elucidating the role of RIPK1 in various biological contexts. -
RIPK3 Inhibitor
UH15-38 is a potent inhibitor of receptor-interacting protein kinase 3 (RIPK3), exhibiting an IC50 of 20 nM. This compound effectively blocks necroptosis activated by influenza A virus (IAV), reducing associated cellular damage. UH15-38 is valuable for research aimed at understanding viral pathogenesis and investigating potential therapeutic approaches for IAV-induced lung injury. -
RIPK3 Inhibitor
GSK840 is a highly potent inhibitor of receptor-interacting protein kinase 3 (RIPK3), exhibiting an IC50 of 0.9 nM for binding to the RIP3 kinase domain and an IC50 of 0.3 nM for inhibiting its kinase activity. This compound provides a valuable tool for studying RIPK3-mediated pathways and their role in programmed cell death and inflammation. GSK840 is applicable in research focused on neurodegenerative diseases, cancer, and immune responses. -
RIPK1/RIPK3 Inhibitor
RIPK1-IN-17 is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1) with a Kd of 17 nM, exhibiting minimal activity against RIPK3. This compound specifically targets necroptosis by inhibiting the phosphorylation of RIPK1, RIPK3, and MLKL, thereby preventing necroptotic cell death while allowing apoptosis to proceed. RIPK1-IN-17 has demonstrated protective effects in mice against hypothermia and mortality, making it a valuable tool for researching necroptosis-related conditions, particularly in the context of inflammatory response syndrome (SIRS). -
RIPK2 Modulator
cRIPGBM chloride is a selective modulator of receptor-interacting protein kinase 2 (RIPK2) that induces caspase 1-dependent apoptosis. This compound effectively disrupts the RIPK2/TAK1 prosurvival complex while promoting the formation of the RIPK2/caspase 1 pro-apoptotic complex. cRIPGBM chloride demonstrates significant anti-tumor efficacy in vivo in animal models, making it a valuable tool for research into glioblastoma multiforme (GBM) and related cancer therapies. Its proapoptotic properties offer insights into mechanisms of cell death and potential therapeutic strategies in cancer treatment. -
RIPK1 Inhibitor
Zharp1-211 is a selective inhibitor of RIPK1 kinase, with an EC50 of 53 nM and a Kd of 8.7 nM. This compound effectively reduces IFN-γ-induced STAT1 activation, presenting significant implications for the study of inflammatory responses. Zharp1-211 is suitable for research applications related to graft-versus-host disease and colon cancer, contributing to investigations into therapeutic strategies for these conditions. -
RIPK1 PROTAC Degrader
LD4172 is a selective RIPK1 PROTAC degrader that exhibits a Ki of 4.8 nM. It facilitates RIPK1 protein degradation through the formation of a ternary complex with RIPK1 and VHL E3 ligase, leading to ubiquitination and proteasomal degradation. LD4172 effectively inhibits TNF-induced classical NF-κB signaling in TRAF2-deficient cells, significantly reducing IκBα phosphorylation and IL-8 production. Additionally, it promotes apoptosis and immunogenic cell death in tumor cells, enhances tumor-infiltrating lymphocyte responses, and sensitizes tumors to anti-PD1 therapy, making it a valuable chemical probe for studying RIPK1-related functions in melanoma and colon cancer research. -
RIPK2 Inhibitor
Zharp2-1 is a potent inhibitor of receptor-interacting protein kinase 2 (RIPK2), which plays a critical role in inflammatory responses. This compound is particularly relevant in the context of inflammatory bowel disease (IBD), demonstrating the ability to modulate immune cell activation in response to muramyl dipeptide (MDP). Zharp2-1 effectively reduces MDP-induced small inguinal peritonitis and alleviates inflammation associated with DNBS-induced large inguinal conjunctivitis, making it a valuable tool for research in models of chronic inflammation and IBD. -
RIPK3 Inhibitor
RIPK3-IN-4 is a potent inhibitor of receptor-interacting protein kinase 3 (RIPK3), primarily known for its role in necroptosis and inflammation. This compound effectively protects HK-2 cells from damage, mitigating necroptosis and inflammatory responses. Additionally, RIPK3-IN-4 demonstrates significant protective effects against kidney damage induced by Cisplatin and ischemia/reperfusion, making it a valuable tool for research into acute kidney injury and related inflammatory conditions. -
RIPK3 Inhibitor
RIPK3-IN-6 is a type I inhibitor targeting Receptor-Interacting Serine/Threonine Kinase 3 (RIPK3), known for its role in programmed necrosis and inflammation. This compound exhibits poor selectivity across the RIPK family, particularly affecting the activity of RIPK2. It serves as a valuable tool for investigating necroptosis pathways and their implications in various diseases, providing insights into signaling processes and therapeutic targets. -
RIPK1 Inhibitor
SZM-1209 is a potent and specific inhibitor of RIPK1, demonstrating a Kd of 85 nM. It exhibits significant anti-necroptotic activity with an EC50 value of 22.4 ± 8.1 nM. SZM-1209 has been shown to mitigate conditions associated with systemic inflammatory response syndrome (SIRS) and acute lung injury (ALI), making it a valuable tool for research in inflammation-related pathologies. -
RIPK2/ALK2 Inhibitor
OD36 is a selective inhibitor of RIPK2 with an IC50 of 5.3 nM, demonstrating potent binding affinity to the ATP pocket of the ALK2 kinase, with a KD of 37 nM. This macrocyclic compound exhibits specific ALK2-directed activity, making it a valuable tool for investigating the roles of these kinases in various biological pathways. Research applications include the exploration of inflammatory signaling and potential therapeutic interventions in related diseases.
